Summary: In this single-centre qualitative substudy of a 6-month multicentre randomised trial, 10 youth (mean age 17.4 years) with type 1 diabetes and suboptimal control (mean baseline HbA1c 10.2%, 87 mmol/mol) described starting advanced hybrid closed-loop (AHCL) therapy. Thematic analysis identified perceived glycaemic improvement alongside a persistent diabetes burden and a clear need for ongoing psychosocial support. This is a hypothesis-generating qualitative study, so no effect sizes or significance testing apply.
PICO Summary
| Element | Detail |
|---|---|
| Population | 10 youth (mean age 17.4 years, SD 2.9; mean diabetes duration 10.7 years) with type 1 diabetes on insulin pump therapy and HbA1c >8.5% (>69 mmol/mol); mean baseline HbA1c 10.2% (87 mmol/mol). Single-centre qualitative substudy nested in a multicentre randomised trial, Australia. |
| Intervention | Advanced hybrid closed-loop therapy (Medtronic MiniMed system) for 6 months, followed by a semistructured interview (single arm; all 10 participants interviewed). |
| Comparison | None. This qualitative substudy had no comparator arm; participants reflected on their own pre-AHCL experience. |
| Outcome | Thematic analysis (no significance testing). Three themes: (1) improved glycaemia despite not using closed loop to its full potential; (2) persistent diabetes burden; (3) a need for increased psychosocial and clinical support. All participants reported satisfaction with improved glucose levels, yet ongoing motivation issues and suboptimal system use persisted. |
Expert Commentary
This is a careful qualitative substudy, and it should be read as such. Its value lies in surfacing the lived experience of a hard-to-reach group, namely youth with type 1 diabetes and persistently high HbA1c, rather than in proving that AHCL therapy works. The themes are coherent and clinically resonant: technology was perceived to help, but motivation, burnout, and the relentless burden of diabetes blunted how fully the system was used. No effect sizes, confidence intervals, or p values are reported, and none should be expected from thematic analysis. The most weighable limitation is the tiny single-centre sample of 10, drawn from one site of a larger trial, which means transferability to other settings and cultures is uncertain and selection effects are plausible. The Medtronic device is named, though the analysis is academic and the framing is not promotional. Can I use this with my patients? Cautiously, yes, as a reminder that handing an adolescent with poor control a closed-loop pump is not a fix on its own. The honest message is that hardware alone is not enough for this group. I would pair any technology start with structured psychosocial support and realistic expectations, and I would welcome larger mixed-methods work that links these experiences to measured glycaemic and quality-of-life outcomes.
References
Roberts A, Dart J, Lloyd S, Bebbington K, Fairchild JM, Ambler GR, et al. “I Think I Could Have Used It Better”: Experiences of Youth with High HbA1c Commencing Advanced Hybrid Closed-Loop Therapy in a Clinical Trial Setting-A Qualitative Research. Pediatr Diabetes. 2024;2024:6260002. doi:10.1155/2024/6260002